No classic psychedelic is FDA-approved for any psychiatric indication, and psilocybin, MDMA and LSD all remain Schedule I — yet patients are asking about them weekly. On July 14, 2026 the FDA published a final clinical trial guidance and a public hearing notice on the same day, and Executive Order 14401 directs priority review. Two hosts separate the regulatory reality from the headlines: where the law actually stands, what to tell a patient asking about ketamine clinics versus psilocybin trials, and which signals are worth watching. Read the guide: https://psychnpfellowship.com/psychedelic-therapy-2026-pmhnp-regulatory-status/